EUVIMEDEUVIMED entdecken
Crossref

Treatment of Chronic Hepatitis D Patients with Pegylated Interferon: A Real-World Experience

Zaigham Abbas, Mohammad S Memon, Hammad Mithani, Wasim Jafri, Saeed Hamid

Antiviral Therapy · 2014-07 · 19 (5) · 463-468

DOI: 10.3851/imp2728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antiviral Therapy, online erschienen am 01.07.2013. Verfasst von Zaigham Abbas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan. drzabbas@gmail.com. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Published experience of treating chronic hepatitis D patients with pegylated interferon (PEG-IFN)-α is limited. The aim of this study was to determine the efficacy of 48 weeks of treatment with PEG-IFN in naive patients outside the clinical trial setting, in the real world.

Methods

Patients with chronic hepatitis D were treated with PEG-IFN. The primary end points were sustained clearance of HDV RNA and normal alanine aminotransferase (ALT) at 24 weeks post-treatment.

Results

The total number of patients treated with PEG-IFN was 104; 91 males, mean age ±sd 30.1 ±10.0 years (range 15–55). Cirrhosis was present in 41 patients. With an intention-to-treat analysis, end of treatment virological response (ETR) was achieved in 44 (42.3%), normalization of ALT in 38 (35%) and a combined response in 23 (22.1%) patients. Sustained virological response (SVR) at 24 weeks post-treatment was seen in 24 (23.1%) patients each for the virological and bio-chemical responses and in 13 (12.5%) as combined response. Both ETR and SVR were associated with a negative HDV RNA at 24 weeks of treatment ( P=0.001 and P=0.000, respectively). Detectable HDV RNA at this point had a positive predictive value of 0.95 (range 0.85–0.99) for detectable RNA at 6 months post-treatment. End of treatment biological response, that is, normal ALT at the end of treatment was also a predictor of ETR and SVR ( P=0.004 and P=0.041, respectively).

Conclusions

Treatment with PEG-IFN for hepatitis D is of limited efficacy. Detectable HDV RNA at 24 weeks of treatment is a predictor for a failed SVR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultAntiviral AgentsFemaleHepatitis D, ChronicHepatitis Delta VirusHumansInterferon alpha-2Interferon-alphaInterferonsMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRisk FactorsTreatment OutcomeViral LoadYoung Adult

Substanzen

Antiviral AgentsInterferon alpha-2Interferon-alphaRecombinant ProteinsPolyethylene GlycolsInterferonspeginterferon alfa-2bpeginterferon alfa-2a

Autor:innen und Institutionen

  • Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan. drzabbas@gmail.com.

Zitieren

APA

Abbas, Z., Memon, M. S., Mithani, H., Jafri, W., & Hamid, S. (2014). Treatment of Chronic Hepatitis D Patients with Pegylated Interferon: A Real-World Experience. Antiviral Therapy, 19(5), 463-468. https://doi.org/10.3851/imp2728

Vancouver

Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of Chronic Hepatitis D Patients with Pegylated Interferon: A Real-World Experience. Antiviral Therapy. 2014;19(5):463-468. doi:10.3851/imp2728

BibTeX
@article{Abbas2014,
  author = {Abbas, Zaigham and Memon, Mohammad S and Mithani, Hammad and Jafri, Wasim and Hamid, Saeed},
  title = {Treatment of Chronic Hepatitis D Patients with Pegylated Interferon: A Real-World Experience},
  journal = {Antiviral Therapy},
  year = {2014},
  volume = {19},
  number = {5},
  pages = {463--468},
  doi = {10.3851/imp2728}
}
Kostenlos starten →